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Abstract
Background: Colorectal cancer (CRC) is the third most common cancer worldwide, and its incidence is expected to
increase to over 2.2 million new cases in 2030. Stage II CRC is classified as localized disease, while stage III CRC has
spread to regional lymph nodes. The 5-year survival rate is over 80% for patients with stage II CRC, but less than
60% for patients with stage III CRC. Proteins, especially plasma proteins that are detectable in easily obtained blood
samples, that differ between stage II and III CRC could be useful for predicting and monitoring disease progression.
CRC displays differences depending on primary tumor location (right colon, left colon, or rectum), and how plasma
protein expression changes during CRC progression from stage II to III depending on primary tumor location is not
well-characterized.
Methods: In this study, we have used Ultra Performance Liquid Chromatography-Ultra Definition Mass
Spectrometry (UPLC-UDMSE)-based proteomics to analyze plasma samples from 83 patients with stage II or III CRC,
followed by statistical and pathway analysis (data are available via ProteomeXchange). The patients were divided
into groups according to tumor stage (II or III) and changes in plasma protein expression between stage II and III
(localized and regional disease) samples were studied both regardless of primary tumor location and also within
each primary tumor location (right colon, left colon, rectum).
Results: We discovered differences in plasma protein expression within all groups analyzed and identified proteins
whose levels changed in one, two, or all three primary tumor locations between stage II and III CRC. Proteins were
identified that could separate the groups compared and pathway analysis by IPA discovered altered pathways
involved in lipid metabolism and inflammation, among others.
Conclusions: Plasma protein expression changes significantly as CRC progresses from stage II to III. While the levels
of certain plasma proteins changed during cancer progression in only one or two primary tumor locations, the
levels of 13 proteins changed in all primary tumor locations and are therefore common to CRC progression.
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Background
Each year, over 1.4 million new cases of colorectal
cancer (CRC) are diagnosed, making it the third most
common cancer worldwide [1]. In addition, the CRC
burden has been predicted to increase by 60% by
2030 [2]. While the 5-year survival rate is more than
60% in countries such as the United States and
Switzerland, it ranges from 28 to 42% in developing
countries [3]. There are also large differences in sur-
vival according to stage of disease – when CRC is de-
tected at an early stage, the 5-year survival rate can
be as high as 90%, but when the disease has spread
to distant organs, it is only 12.5% [4, 5]. According to
the TNM classification of malignant tumors, stage II
CRC includes tumors with no regional lymph node
metastasis. Stage III CRC is characterized by regional
lymph node metastasis in any number of regional
lymph nodes [6]. The TNM classification is anatomic-
ally-based and, although widely used, does not take
into account additional patient or disease characteris-
tics known to affect survival in CRC, such as age,
gender, and primary tumor location. In patients with
stage II and III CRC, the TNM system struggles to
clearly distinguish groups of patients with different
prognosis, especially in patients who receive adjuvant
chemotherapy [7]. For stage II CRC patients the 5-
year survival rate is 82,5%, and for stage III patients
the 5-year survival rate is 59,5% [8].
Differences between tumors arising in the right and
left colon have been well documented, and it has
been suggested that right- and left-sided colon cancer
should be considered to be separate entities [9–11].
Differences exist in embryologic origin, gross macro-
scopic pathology, and clinical presentation, with right-
sided colon cancer typically presenting at a more
advanced stage. Right-sided colon cancer has also
been found to be more frequent in older people and
women and to have a poorer prognosis than left-sided
colon cancer [12, 13]. While colorectal cancer
includes cancer both in the colon and rectum, rectal
cancer differs in several ways from cancer in the
colon, such as having a greater risk of local
recurrence [14, 15]. Rectal cancer also tends to more
frequently display mutations in genes such as TP53
than colon cancer [15, 16]. How plasma protein ex-
pression changes during CRC progression from stage
II to III depending on primary tumor location is
something that has not previously been studied, as far
as we know.
Mass spectrometric proteomic analysis is widely used
to analyze the levels of hundreds of plasma proteins sim-
ultaneously and in efforts to elucidate molecular features
of diseases at the protein level. The blood proteome is
dynamic and reflects the state of the host due to the
perfusion of organs, therefore also reflecting the pres-
ence of diseases such as cancer. Biomarkers detectable
from blood samples are useful due to the ease of sample
collection [17, 18]. Previous proteomic studies of CRC
have mainly attempted to find new biomarker candidates
for the early detection of CRC and have compared sam-
ples from CRC patients and healthy controls. [19–21].
However, a study by Surinova et al. discovered different
plasma protein signatures able to predict factors such as
prognosis, regional tumor localization, and disease dis-
semination [22]. Few studies have used samples from
cancer patients only, without the addition of healthy
controls, although we have previously analyzed serum
protein expression in a small set of CRC patients with
varying C-reactive protein levels and survival times [23].
At the time of diagnosis in clinical settings, discerning
cancer from healthy controls is not a requirement for
differential diagnosis. Here, differences between various
stages of cancer or prognostic determination become
more important.
In this study, we have used Ultra Performance Liquid
Chromatography-Ultra Definition Mass Spectrometry
(UPLC-UDMSE)-based proteomics to analyze plasma
samples from CRC patients. The aim of this study was
to study if there were observable differences in plasma
protein expression between stage II and III CRC pa-
tients. This study provides new insights into how plasma
protein expression differs during CRC progression, both
regardless of and depending on primary tumor location.
Methods
Patient samples
This study used preoperative plasma samples from a
total of 84 CRC patients, of which 37 were male and 47
female. This study included patients with stage II or
stage III CRC who underwent surgical resection with
curative intent in the Department of Surgery, Helsinki
University Hospital, between 2000 and 2007. Plasma
samples were stored at − 80 °C until processed as de-
scribed below. We deliberately excluded patients with
other cancers, a previous history of HNPCC, FAP, ul-
cerative colitis, Crohn’s disease, or mucinous tumors
from this study. Detailed patient characteristics are given
in Additional file 1. The clinical data was obtained from
patient records, the survival data from the Population
Register Centre of Finland, and the cause of death for all
the deceased from Statistics Finland. Written informed
consent was obtained from all patients prior to collect-
ing samples. This study conformed to the standards set
by the Declaration of Helsinki and was approved by the
Surgical Ethics Committee of Helsinki University Hos-
pital (Dnro HUS 226/E6/06, extension TMK02 §66
17.4.2013).
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Sample processing and digestion
The plasma samples were processed as follows. The
plasma samples were first thawed, after which top 12
protein depletion was carried out using the TOP12
protein depletion kit (Pierce, ThermoFisher, MA,
USA) according to the manufacturer’s instructions.
The Pierce BCA assay kit (Pierce, ThermoFisher, MA,
USA) was used to determine the protein concentra-
tion in each sample, and the amount of plasma
equivalent to 100 μg of protein was aliquoted and
dried using a SpeedVac (Savant, ThermoFisher, MA,
USA). The dried plasma was dissolved in 35 μl Tris
buffer (50 mmol/L, pH 7.8), which contained 6M
urea, and 1.8 μl of dithiothreitol (DTT, 200 mmol/L)
was then added to each sample. The samples were
shaken for 1 h at room temperature, and then 7 μl of
iodoacetamide (200 mmol/L) per sample was added.
Samples were shaken for 1 h at room temperature,
and 7 μl of DTT (200 mmol/L) was added to each
sample afterwards, and the samples were shaken for
another hour at room temperature. The samples were
then diluted with 270 μl mQ water per sample and
trypsin was added at a ratio of 1:50 trypsin to pro-
tein. The samples were digested at 37 °C overnight,
after which 30 μg of tryptic peptides were cleaned
using C18 spin columns (Pierce, ThermoFisher, MA,
USA). The cleaned peptides were then dissolved in
86 μl of 0.1% formic acid containing 12.5 fmol/μl of
Hi3 spike-in standard peptides (Waters, MA, USA)
for quantification.
Ultra performance liquid chromatography-ultra definition
mass spectrometry and quantification
UPLC-UDMSE
For UPLC-UDMSE, four μl of each sample, equivalent to
~ 1.4 μg total protein, was injected to a nanoACQUITY
UPLC system (Waters Corporation, MA, USA).
TRIZAIC nano-Tile 85 μm× 100mm HSS-T3u wTRAP
was used as a separation device. Samples were loaded,
trapped, and washed for two minutes with 8.0 μl 1% B
and the analytical gradient used was as follows: 0–1 min
1% B, at 2 min 5% B, at 65 min 30% B, at 78 min 50% B,
at 80 min 85% B, at 83 min 85% B, at 84 min 1% B, and
at 90 min 1% B with 450 nL/min. Buffer A was 0.1%
formic acid in water while buffer B was 0.1% formic acid
in acetonitrile. Data were acquired in data-independent
acquisition fashion using UDMSE mode with a Synapt
G2-S HDMS (Waters Corporation, MA, USA). Calibra-
tion was performed with sodium iodide clusters over a
mass range of 50–2500m/z by infusing 2 μg/μl sodium
iodide solution in 50/50 2-propanol/water into the mass
spectrometer. 10% of the samples were run in triplicate
and the median coefficient of variation (%CV) of the
dataset was 4.36%.
Data analysis
Data analysis and label-free quantification were performed
as previously described [23–25]. In summary, the raw files
were imported to Progenesis QI for proteomics (Nonlin-
ear Dynamics, Newcastle, UK). Post-acquisition mass cor-
rection was done when the raw data was imported into
Progenesis with a with a lock mass ion of M +H+
556.2771m/z. Leucine enkephalin (C25H37O7, 1 ng/μl in
50:50 acetonitrile:water + 0,1% formic acid) was infused
into the reference sprayer at 300 nl/min for this purpose.
Default parameters were used for peak picking and
alignment, while the peptide identification was done
against Uniprot human FASTA sequences (release 2018_
04). A ClpB protein sequence (CLPB_ECOLI (P63285))
was inserted for label-free quantification. Fixed modifi-
cation at cysteine (carbamidomethyl) and variable at me-
thionine (oxidation) were used. Trypsin was used as a
digesting agent, with one missed cleavage allowed. Frag-
ment and peptide error tolerances were set to automatic
settings, and the false discovery rate (FDR) was set to
less than 2%. For ion matching, one or more ion frag-
ments per peptide, three or more fragments per protein,
and one or more peptides per protein were required,
which are the default parameters.
The parsimony principle was used to group the proteins
and peptides unique to the protein were also reported. Pro-
genesis QI for proteomics does not follow a strict
parsimonious approach due to over-stringency, something
that has been previously noted [26]. In the case of a conflict
where two proteins were found with common peptides, the
protein with fewer peptides was absorbed into the protein
with more peptides. All relevant proteins are listed as a
group under the lead protein with the highest coverage or
score if the coverage of two or more proteins are equal.
Quantification was performed using the lead identity pep-
tide data. Further details can be found on the Nonlinear
Dynamics’ website (www.nonlinear.com).
Further analysis
The differences between the groups were analyzed
using the Mann-Whitney U test. Principal Compo-
nent Analysis (PCA) was performed using Progenesis
QI for proteomics in order to help visualize the
differences between the groups. Further analysis in-
cluded Orthogonal Projections to Latent Structures
Discriminant Analysis (OPLS-DA) modeling, used to
classify the proteins expressed in the different
groups, from which an S-plot was generated. All
proteins were used as input for OPLS-DA modeling,
but the passing criteria were a p (corr) cutoff value
of greater than ±0.6 and a loading (p [1]) of between
±0.1. These S-plot criteria-passing proteins also had
to pass the cutoff of a Mann-Whitney U test p-value
of less than 0.05 for added stringency. Pathway
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analysis was performed using Ingenuity Pathway
Analysis (IPA) (QIAGEN Bioinformatics, Redwood
City, CA) and the String 11.0 Database (accessed at
https://string-db.org). Only proteins that passed the
cutoff of a Mann-Whitney U test p-value of less
than 0.05 were used for pathway analysis. The set-
tings used for String pathway analysis were highest
confidence and the active interaction sources used
were “Experiments” and “Databases”. All other active
interaction sources were excluded.
Results
Protein identification and comparisons
In this study, we analyzed plasma samples from 84 CRC
patients that were divided into groups depending on
tumor stage. One sample was not successfully digested
and was subsequently excluded from further analysis,
giving a total of 83 CRC patients, of which 34 had stage
II CRC and 49 had stage III CRC. The patients included
in this study are given and the excluded sample is
marked in Additional file 1. We quantified a total of 224
proteins containing two or more unique peptides, and
these proteins were used for further analysis. Proteins
with p-values greater than 0.05 were not considered to
be significantly different. The full list of proteins identi-
fied with relevant data is given in Additional file 2.
The plasma samples in this study were divided into
different groups according to tumor stage (II or III), as
well as according to tumor stage and location in the
colon (right colon, left colon, rectum). The plasma sam-
ples in this study were therefore analyzed and the pro-
tein expression compared between all stage II and III
CRC samples as well as between samples from patients
with stage II and III cancer in the right colon, left colon,
or rectum separately. Samples were also compared be-
tween stage II and III cancer in all primary tumor loca-
tions together. Proteins with p-values of less than 0.05
were considered to have significantly different levels be-
tween the groups.
Comparison of protein expression between patients with
stage II and III CRC
When plasma samples from all stage II (n = 34) and
stage III (n = 49) CRC patients were compared (regard-
less of primary tumor location), a total of 79 proteins
passed the cutoff of a Mann-Whitney U test p-value of
less than 0.05 (Additional file 3 A). Of these proteins, 77
displayed higher levels in patients with stage II CRC, in-
dicating that their concentrations decreased as CRC pro-
gressed from stage II to III. Only two proteins, MORC
family CW-type zinc finger protein 2 (MORC2) and Fila-
min-A-interacting protein 1 (FILIP1), had higher levels
in patients with stage III cancer, indicating that these
two proteins may be linked to disease progression and
regional metastasis.
The PCA biplots showing all proteins (with two or more
unique peptides) and, separately, only those proteins that
passed the cutoff of a Mann-Whitney U test p-value of less
than 0.05 did not show a separation between the two
groups. OPLS-DA modeling and the S-plot generated from
this model identified one protein that passed all three cri-
teria mentioned previously, which was Histidine protein
methyltransferase 1 homolog (METTL18). METTL18 dis-
played higher levels in patients with stage II CRC and is
given with its relevant data in Additional file 4 A.
Pathway analysis by IPA found multiple canonical
pathways that were enriched in this dataset, such as
LXR/RXR and FXR/RXR activation, the complement
system, and acute phase response signaling. Pathway
analysis by IPA also generated networks of protein-pro-
tein interactions, and the top network was found to be
associated with the following functions: humoral im-
mune response, inflammatory response, and develop-
mental disorder (Additional file 5).
Comparison of protein expression between patients with
right-sided stage II and III CRC
When samples from patients with right-sided stage II (n =
11) and stage III (n = 16) CRC were compared, a total of
97 proteins passed the cutoff of a Mann-Whitney U test
p-value of less than 0.05 (Additional file 3B). Two of these
proteins, MORC2 and Ephrin type-A receptor 5 (EPHA5),
displayed higher levels in samples from patients with
right-sided stage III colon cancer. Levels of the other 95
proteins were higher in patients with stage II cancer in the
right colon, indicating a decrease in expression from stage
II to III cancer in the right colon. MORC2 displayed the
largest fold change (5.7) of all 97 proteins in this group,
with higher levels in samples from patients with stage III
cancer in the right colon.
The PCA biplot when all proteins were considered
showed a partial separation between samples from pa-
tients with right-sided stage II and III colon cancer
(Fig. 1a). When only proteins with a Mann-Whitney U
test p-value of less than 0.05 were considered, the separ-
ation became clearer, which was expected due to consid-
ering only differentially expressed proteins (Fig. 1b).
OPLS-DA modeling and the S-plot generated from this
model identified 21 plasma proteins that passed all three
criteria mentioned previously (a p (corr) cutoff value of
greater than ±0.6, a loading (p [1]) of between ±0.1, and
a Mann-Whitney U test p-value of less than 0.05) and
could discriminate between samples from patients with
right-sided stage II and III colon cancer. The S-plot is
shown in Fig. 1c and the 21 proteins are given in Table 1.
The S-plot criteria-passing protein with the largest fold
change (5.7) was MORC2, which had higher levels in
Holm et al. Translational Medicine Communications            (2019) 4:14 Page 4 of 12
AB
C
Fig. 1 Separation between proteins expressed in samples from patients with right-sided stage II and III CRC. a shows the PCA biplot when all
proteins were considered b shows the PCA biplot when only proteins that passed the cutoff of a Mann-Whitney U test p-value of less than 0.05
were considered. Blue dots represent samples from patients with stage II cancer in the right colon and purple dots represent samples from
patients with stage III cancer in the right colon. c shows the S-plot generated by OPLS-DA modeling. The upper right quadrant of the S-plot, with
positive values, shows proteins with higher levels in samples from patients with right-sided stage III CRC. The lower left quadrant, with negative
values, shows proteins with higher levels in samples from patients with right-sided stage II CRC
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Table 1 The S-plot proteins differing between samples from patients with right-sided stage II and III CRC
Accession Peptide
count
Unique
peptides
Confidence
score
Mann-
Whitney U
test p-value
Fold change (right
colon stage II/right
colon III)
Protein name Gene
name
p
[1]
p
(corr)
[1]
O95568 8 3 32,4 4,37E−05 1,6 Histidine protein
methyltransferase 1 homolog
METTL18 −0,
02
−0,86
P09429 5 2 29,5 1,43E− 04 1,8 High mobility group protein B1 HMGB1 −0,
03
− 0,
82
P68032;
P62736;
P68133;
P63267
21 3 208,1 1,66E−03 1,8 Actin_ alpha cardiac muscle 1 ACTC1 −0,
04
−0,82
P01344 7 4 27,5 1,66E−03 1,4 Insulin-like growth factor II IGF2 −0,
02
−0,77
Q96KN2 19 15 128,0 3,08E−03 1,4 Beta-Ala-His dipeptidase CNDP1 −0,
06
−0,76
P04083 17 8 99,3 1,95E−03 1,4 Annexin A1 ANXA1 −0,
06
−0,71
Q9Y4B5 4 2 19,1 8,64E−04 1,9 Microtubule cr s-linking factor 1 MTCL1 −0,
01
−0,69
H7BZ55 9 6 52,9 8,35E−03 1,4 Putative ciliary rootlet coiled-coil
protein 2
CROCC2 −0,
05
−0,68
Q562R1 12 4 95,6 2,28E−02 1,2 Beta-actin-like protein 2 ACTBL2 −0,
02
−0,66
P00740 13 10 71,8 6,14E−04 1,4 Coagulation factor IX F9 −0,
03
−0,65
Q6UB98 6 2 36,6 4,79E−03 1,5 Ankyrin repeat domain-
containing protein 12
ANKRD12 −0,
06
−0,65
H3BMM5 3 2 13,7 1,20E−03 1,4 Uncharacterized protein −0,
02
−0,65
P02775 9 7 66,0 8,00E−05 1,5 Platelet basic protein PPBP −0,
04
−0,63
Q14520 24 18 158,5 1,09E−02 1,4 Hyaluronan-binding protein 2 HABP2 -0,
04
-0,63
P23508 5 3 27,9 1,09E-02 1,2 Colorectal mutant cancer protein MCC -0,
03
-0,63
A5A3E0;
Q6S8J3;
P0CG39;
Q9BYX7;
E7EQ34;
O14653
52 14 289,7 1,73E-04 1,4 POTE ankyrin domain family
member F
POTEF -0,
03
-0,62
Q15166 6 2 62,1 1,24E-02 2,9 Serum paraoxonase/lactonase 3 PON3 -0,
05
-0,61
O75882 16 12 98,9 4,92E-02 1,2 Attractin ATRN -0,
03
-0,60
P35858;
Q2M5E4
34 28 275,0 2,03E-02 1,4 Insulin-like growth factor-binding
protein complex acid labile
subunit
IGFALS -0,
08
-0,60
P43251 11 7 75,6 1,24E-02 1,5 Biotinidase BTD -0,
03
-0,60
Q9Y6X9 5 3 27,1 6,14E-04 −5,7 MORC family CW-type zinc finger
protein 2
MORC2 0,
02
0,62
These proteins passed the criteria for OPLS-DA modeling and also had a Mann-Whitney U test p-value of less than 0.05. Accession, peptide count, unique
peptides, confidence score, p-value, fold change, protein name, gene name, covariance (p [1]), and correlation (p (corr) [1]) are given in the table
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patients with right-sided stage III colon cancer. MORC2
was also the only one of the 21 proteins identified that
showed higher plasma levels in samples from patients
with stage III cancer in the right colon.
Pathway analysis by IPA found similar canonical path-
ways as in the analysis of all stage II and III samples to
be enriched in this dataset (Additional file 6). The top
network of protein-protein interactions also generated
by IPA is shown in Fig. 2a. This network was found to
be associated with the following functions: hematological
system development and function, organismal functions,
and hematological disease (Additional file 7). Pathway
analysis was also performed using the String database,
and the protein-protein interaction network generated
for this dataset is shown in Fig. 2b. This network shows
that many of the proteins identified interact directly with
each other in various ways. String shows direct connec-
tions linking the proteins used as input, whereas IPA fills
in the gaps by adding proteins not detected in this study
that are known to interact with the proteins detected.
Comparison of protein expression between patients with
left-sided stage II and III CRC
The plasma samples from patients with left-sided stage
II (n = 10) and stage III (n = 16) colon cancer were
analyzed separately. A total of 38 proteins passed the
cutoff of a Mann-Whitney U test p-value of less than
0.05 (Additional file 3C). Of these proteins, 10 displayed
higher levels in the plasma of patients with stage III
compared to stage II cancer in the left colon, showing
that their concentrations in plasma increase as CRC pro-
gresses. The remaining 28 proteins displayed lower levels
in left-sided stage III colon cancer, showing a decrease
in plasma levels from stage II to III. The protein with
the largest fold change observed (8.5) was Serum amyl-
oid A-1 protein (SAA1), which displayed higher levels in
patients with stage II cancer.
The PCA biplots when all proteins were considered
and when only proteins with a Mann-Whitney U test p-
value of less than 0.05 were considered did not show a
separation between the groups. OPLS-DA modeling and
the S-plot generated from this model identified 7 pro-
teins (shown in Additional file 4B) that passed all three
criteria mentioned previously (figures not shown). These
proteins could therefore separate samples from patients
with stage II and stage III cancer in the left colon. All 7
proteins identified showed higher plasma levels in pa-
tients with stage II cancer in the left colon, with Keratin,
type I cytoskeletal 10 (KRT10) having the largest fold
change (1.7).
A B
Fig. 2 Pathway analysis for samples from patients with right-sided stage II and III CRC. a shows the top protein-protein interaction network
generated by IPA. Proteins in red are proteins that were identified in our study and which displayed higher levels in patients with stage II CRC in
the right colon when compared to patients with stage III CRC in the right colon. Proteins in white are proteins that, although not identified in
our study, play roles in this network and interact with the proteins identified. b shows the protein interaction network generated by String
analysis. The network shows known, direct protein-protein interactions from experiments and databases, without the addition of intermediate
proteins not detected in this study, which IPA adds. Only proteins that passed the cutoff of having a Mann-Whitney U test p-value of less than
0.05 were used for pathway analysis
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Pathway analysis by IPA found similar canonical
pathways to be enriched in this dataset as in the pre-
vious groups, although fewer pathways were found.
The top network of protein-protein interactions gen-
erated by IPA was found to be associated with the
following functions: dermatological diseases and con-
ditions, developmental disorder, and hereditary dis-
order (Additional file 8).
Comparison of protein expression between patients with
stage II and III rectal cancer
The plasma samples from patients with stage II (n = 13)
and stage III (n = 17) rectal cancer were also analyzed
separately. A total of 83 proteins passed the cutoff of a
Mann-Whitney U test p-value of less than 0.05 (Add-
itional file 3D). Only two proteins (Extracellular super-
oxide dismutase [Cu-Zn] (SOD3) and C-reactive protein
(CRP)) displayed higher levels in samples from patients
with stage III rectal cancer. Levels of the other 81 pro-
teins were all lower in samples from patients with stage
III rectal cancer. The protein with the largest fold
change (9.3) was Serum paraoxonase/lactonase 3
(PON3). PON3 displayed higher plasma levels in pa-
tients with stage II rectal cancer.
The PCA biplots when all proteins were considered
and when only proteins with a Mann-Whitney U test
p-value of less than 0.05 were considered did not
show a clear separation between the groups. OPLS-
DA modeling and the S-plot generated from this
model (data not shown) identified a total of 24 pro-
teins (shown in Additional file 4C) that passed all
three criteria previously mentioned and which were
therefore able to differentiate between samples from
patients with stage II and III rectal cancer. All 24
proteins identified here displayed higher levels in
stage II rectal cancer, with Keratin, type I cytoskeletal
16 (KRT16) having the largest fold change (8.4).
Pathway analysis by IPA found similar canonical
pathways as in the previous analyses to be enriched
in this dataset. The top network of protein-protein in-
teractions generated by IPA was found to be associ-
ated with the following functions: humoral immune
response, inflammatory response, and developmental
disorder (Additional file 9).
Venn diagram analysis for comparison of protein
expression between primary tumor locations during
cancer progression
In order to compare the protein expression between all
three different primary tumor locations during cancer
progression, we compared the proteins that significantly
differed (those with a Mann-Whitney U test p-value of
less than 0.05) between stage II and III CRC in each pri-
mary tumor location (right colon, left colon, or rectum)
with each other. In other words, we compared the pro-
teins that passed the cutoff in the groups right colon
stage II and III (97 proteins, found in Additional file 3B),
left colon stage II and III (38 proteins, Additional file
3C), and rectum stage II and III (83 proteins, Additional
file 3D) against each other. The Venn diagram in Fig. 3
shows how the proteins that differ between stage II and
III CRC overlap between different primary tumor loca-
tions, and each circle contains the total number of pro-
teins that significantly differed between stage II and III
CRC in that primary tumor location. The proteins that
overlap between primary tumor locations indicate
changes in plasma protein expression that are common
to two or more locations during cancer progression.
The figure shows the number of proteins whose ex-
pression differs between samples from patients with
stage II and III CRC and their relation to primary tumor
location. Proteins whose expression differed between
samples from patients with stage II and III CRC in one,
two, or all three possible primary tumor locations were
identified.
Levels of 44 plasma proteins differed between sam-
ples from patients with stage II and III cancer in the
right colon only (Additional file 10A), while levels of
11 proteins differed between samples from patients
with stage II and III cancer in the left colon only
(Additional file 10B). Levels of 30 proteins differed
between samples from patients with stage II and III
rectal cancer only (Additional file 10C). There were
Fig. 3 Venn diagram of plasma proteins whose levels changed
during CRC progression in all locations
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33 proteins whose levels differed between samples
from patients with stage II and III cancer both in the
right colon and rectum (Additional file 11A), while
levels of 7 proteins differed between samples from pa-
tients with stage II and III cancer in both the right
and left colon (Additional file 11B). Levels of 7 other
proteins differed between samples from patients with
stage II and III cancer in both the left colon and rec-
tum (Additional file 11C). Levels of 13 proteins dif-
fered between samples from patients with stage II
and III CRC regardless of primary tumor location.
Changes in the levels of these 13 proteins were there-
fore common to CRC progression for all locations
and are given in Table 2.
All of the 33 proteins whose levels differed between
samples from patients with stage II and III cancer in both
the right colon and rectum displayed higher levels in stage
II cancer. Among the 7 proteins whose levels differed be-
tween samples from patients with stage II and III cancer
in both the right and left colon, most displayed higher
levels in stage II CRC, although 3 proteins displayed
higher levels in samples from patients with stage III cancer
in the left colon. Of the 7 proteins whose levels differed
between samples from patients with stage II and III cancer
in the left colon and rectum, all had higher levels in stage
II CRC, except for one protein (Kinesin-like protein
KIF16B) that displayed higher levels in samples from pa-
tients with stage III cancer in the left colon.
Levels of 13 proteins were significantly different be-
tween samples from patients with stage II and III CRC
regardless of primary tumor location. Levels of all 13
proteins were higher in samples from patients with stage
II than stage III cancer in the right colon and rectum,
indicating a decrease in plasma levels as CRC pro-
gressed. Levels of four proteins were higher in samples
from patients with stage III cancer in the left colon, indi-
cating an increase as cancer progressed from stage II to
III, while levels of the remaining 9 proteins were higher
in stage II cancer in the left colon. The protein with the
largest fold change in all three groups was PON3. Sur-
prisingly, PON3 displayed higher levels in samples from
patients with stage II cancer in the right colon and rec-
tum, but higher levels in samples from patients with
stage III cancer in the left colon.
Discussion
In this study, we discovered differences in plasma pro-
tein expression between stage II and III CRC patients,
both regardless of and depending on primary tumor lo-
cation, and also identified proteins whose levels changed
in only one, two, or all three primary tumor locations
between stage II and III CRC. These results are interest-
ing as they show that stage II and III tumors in the right
colon, left colon, or rectum lead to the expression of dif-
ferent proteins to such extent that these differences can
be detected in plasma samples. While a study by
Table 2 The Venn diagram proteins whose levels differed during CRC progression in all locations
Proteins whose plasma levels differed between samples from patients with stage II and III cancer in all locations
Accession Peptide
count
Unique
peptides
Confidence
score
Protein name Gene
name
Notes
Q15166 6 2 62,1 Serum paraoxonase/lactonase 3 PON3 *
P02766 22 19 214,4 Transthyretin TTR
P02775 9 7 66,0 Platelet basic protein PPBP *
O95568 8 3 32,4 Histidine protein methyltransferase 1
homolog
METTL18
Q12805 9 8 51,7 EGF-containing fibulin-like
extracellular matrix protein 1
EFEMP1
Q8TE85 6 3 28,7 Grainyhead-like protein 3 homolog GRHL3
P05455 5 3 28,9 Lupus La protein SSB *
A6NMZ7;P51570;Q13158;Q6NT55 5 2 24,3 Collagen alpha-6(VI) chain COL6A6
P09871 54 47 387,7 Complement C1s subcomponent C1S
O75882 16 12 98,9 Attractin ATRN
P23508 5 3 27,9 Colorectal mutant cancer protein MCC *
P02790;P51687;Q00973;Q04917;Q5T013;Q9NXR7;
Q9NZ08;Q9Y2H2;Q9Y2K5;V9GYY9
182 150 1011,0 Hemopexin HPX
P07357 35 34 217,4 Complement component C8 alpha
chain
C8A
These 13 proteins are those whose changes in levels were common to CRC progression regardless of tumor location. Accession, peptide count, unique peptides,
confidence score, protein name, and gene name are given in the table. The proteins with higher levels in samples from patients with left-sided stage III than
stage II CRC are marked with a *. All other proteins had higher levels in patients with stage II cancer
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Surinova et al. previously investigated differences in
plasma protein expression between CRC tumors with
different stage and location, their study focused more on
biomarkers signatures comprised of several proteins ra-
ther than individual proteins [22].
In our current study, MORC2 displayed significantly
higher levels in the plasma of stage III CRC patients,
both when all stage II and III samples were compared
and when only samples from the right and left colon
were compared. MORC2 is a protein with roles in chro-
matin remodeling, facilitating DNA damage repair, and
promoting lipogenesis. Mutations in MORC2 promote
invasion and metastasis in triple-negative breast cancer
[27]. MORC2 has also been shown to be upregulated in
liver cancer and contribute to features such as prolifera-
tion and metastasis [28]. In lung cancer, MORC2 is also
upregulated and enhances tumor growth by promoting
angiogenesis [29]. In CRC, MORC2 has been shown to
inhibit N-myc downstream regulated gene 1 (NDRG1), a
metastasis suppressor, which promotes cell migration,
invasion, and lung metastasis. This study also showed
that MORC2 was upregulated in CRC tissues, and high
expression was found to be associated with lymph node
metastasis [30]. We found that MORC2 levels are higher
in plasma samples from patients with lymph node posi-
tive CRC, and the findings of these studies together indi-
cate that MORC2 is of interest as a new biomarker,
although further studies are needed to elucidate its role
in CRC.
Here, we also identified plasma proteins whose expres-
sion changed between stage II and III cancer in one,
two, or all three primary tumor locations. Levels of cer-
tain plasma proteins changed between stage II and III
cancer only in the right colon, left colon, or rectum. Sur-
prisingly, there were more proteins that were common
between cancer in the right colon and rectum (33 pro-
teins) than between cancer in the left colon and rectum
(7 proteins), even though the right colon and left colon
are anatomically more similar and the left colon and rec-
tum are anatomically closer to each other. Levels of 13
proteins changed between samples from patients with
stage II and III cancer in all primary tumor locations.
These 13 proteins were therefore common to stage II to
III cancer progression and could be of use in predicting
disease progression from local to regional disease, al-
though further validation is needed.
Pathway analysis by IPA identified LXR/RXR activation
and FXR/RXR activation as the two most enriched path-
ways both when all stage II and III samples were analyzed,
as well as when stage II and III samples were analyzed
separately between samples from the right colon, left
colon, and rectum. LXRs are nuclear receptors that play
important roles in cholesterol metabolism as well as in the
biosynthesis and metabolism of very low-density
lipoproteins [31]. FXRs, also nuclear receptors, regulate
bile acid synthesis and various aspects of lipid and glucose
metabolism. LXRs and FXRs both form heterodimers with
RXRs [32, 33]. Lipid metabolic reprogramming occurs in
cancer cells, with specific alterations in various aspects of
lipid metabolism being seen [34, 35]. MORC2 has been
found to interact with ATP citrate lyase (ACLY), which
catalyzes the formation of acetyl-coenzyme A, which is
important in lipid and cholesterol metabolism. In breast
cancer cells, MORC2 promotes ACLY activation, giving
MORC2 a role in lipogenesis [36]. PON3 is primarily lo-
calized to the high-density lipoprotein (HDL) fractions of
plasma and is synthesized in the liver [37]. PON3 also
possesses anti-inflammatory properties, and depletion of
PON3 has been correlated with the pro-inflammatory ac-
tivity of HDL [38]. Our findings that plasma levels of
MORC2 and PON3 change between stage II and III CRC
in various locations indicate that lipid metabolism is al-
tered during CRC progression. The enrichment of lipid
metabolism-associated pathways found by IPA further
strengthens these findings.
Here, we observed changes in the levels of multiple
plasma proteins between stage II and III CRC, both
when all samples were compared and when samples
were analyzed separately according to tumor location.
These proteins could potentially be of use in predicting
disease progression in a non-invasive way through blood
sampling after further studies and large-scale validation.
We discovered multiple plasma proteins whose levels
only changed during cancer progression in the right
colon, left colon, or rectum, as well as proteins whose
levels changed in two or all locations. This further sup-
ports the notion that right- and left-sided CRC signifi-
cantly differ from each other and that rectal cancer
differs from colon cancer. The strengths of this study in-
clude the number of samples analyzed and the multiple
groups between which comparisons were made. This
study was limited by the lack of CRC tissue samples, as
it would have been interesting to relate plasma protein
expression to tissue protein expression. This study is
one of very few studies showing that differences in
plasma protein expression can be seen between patients
with stage II and III CRC, both regardless of and within
different primary tumor locations.
Conclusions
In this study, we found differences in plasma protein ex-
pression between patients with stage II and III CRC, both
when samples were compared regardless of and according
to primary tumor location. This is the first study to show
that CRC progression from stage II to III has distinct,
measurable effects on plasma protein expression and that
plasma protein expression differs and overlaps during can-
cer progression depending on primary tumor location.
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Additional files
Additional file 1: Information about the colorectal cancer patients
included in this study. The table shows patients’ gender, age at
operation, tumor stage, location, and sample code. (XLSX 13 kb)
Additional file 2: The 224 proteins with two or more unique peptides
quantified in this study. This table shows all proteins with two or more unique
peptides that were quantified in this study. Accession, peptide count, unique
peptides, protein name, gene name, and normalized abundance of each
protein in each sample are given in the table. (XLSX 283 kb)
Additional file 3: The proteins that passed the cutoff of a Mann-
Whitney U test p-value of less than 0.05 in the different groups.
Additional file 3A shows the 79 proteins that passed the cutoff when all
stage II and III samples were compared. Additional file 3B shows the 97
proteins that passed the cutoff when samples from patients with right-
sided stage II and III CRC were compared, and Additional file 3C shows
the 38 proteins that passed the cutoff when samples from patients with
left-sided stage II and III CRC were compared. Additional file 3D shows
the 83 proteins that passed the cutoff when samples from patients with
stage II and III rectal cancer were compared. Accession, peptide count,
unique peptides, confidence score, p-value, fold change, protein name,
and gene name are given in the tables. (XLSX 40 kb)
Additional file 4: The S-plot proteins that passed the criteria for OPLS-
DA modeling and also had a Mann-Whitney U test p-value of less than
0.05. Additional file 4A shows the one protein that passed all three
criteria when all stage II and III samples were compared, and Additional
file 4B shows the 7 proteins that passed all three criteria when samples
from patients with left-sided stage II and III CRC were compared.
Additional file 4B shows the 24 proteins that passed all three criteria
when samples from patients with stage II and III rectal cancer were
compared. Accession, peptide count, unique peptides, confidence score,
p-value, fold change, protein name, gene name, covariance (p [1]), and
correlation (p (corr) [1]) are given in the tables. (XLSX 14 kb)
Additional file 5: The results of IPA pathway analysis when all samples
from patients with stage II and III CRC were compared. This file shows
the results of Ingenuity Pathway Analysis when all stage II and III samples
were compared. It includes information about the top canonical
pathways enriched and the protein-protein networks enriched and their
associated functions. Only proteins that passed the cutoff of having a
Mann-Whitney U test p-value of less than 0.05 were used for pathway
analysis. (PDF 86 kb)
Additional file 6: The canonical pathways enriched in the group of
patients with right-sided stage II and III CRC. This figure shows the top
canonical pathways enriched when samples from patients with right-sided
stage II and III CRC were compared using Ingenuity Pathway Analysis. Only
proteins that passed the cutoff of having a Mann-Whitney U test p-value of
less than 0.05 were used for pathway analysis. (PDF 20 kb)
Additional file 7: The results of IPA pathway analysis when samples
from patients with right-sided stage II and III CRC were compared. This
file shows the results of Ingenuity Pathway Analysis when samples from
patients with right-sided stage II and III CRC were compared. It includes
information about the top canonical pathways enriched and the protein-
protein networks enriched and their associated functions. Only proteins
that passed the cutoff of having a Mann-Whitney U test p-value of less
than 0.05 were used for pathway analysis. (PDF 83 kb)
Additional file 8: The results of IPA pathway analysis when samples
from patients with left-sided stage II and III CRC were compared. This file
shows the results of Ingenuity Pathway Analysis when samples from
patients with left-sided stage II and III CRC were compared. It includes
information about the top canonical pathways enriched and the protein-
protein networks enriched and their associated functions. Only proteins
that passed the cutoff of having a Mann-Whitney U test p-value of less
than 0.05 were used for pathway analysis. (PDF 85 kb)
Additional file 9: The results of IPA pathway analysis when samples
from patients with stage II and III rectal cancer were compared. This file
shows the results of Ingenuity Pathway Analysis when samples from
patients with stage II and III rectal cancer were compared. It includes
information about the top canonical pathways enriched and the protein-
protein networks enriched and their associated functions. Only proteins
that passed the cutoff of having a Mann-Whitney U test p-value of less
than 0.05 were used for pathway analysis. (PDF 85 kb)
Additional file 10: The proteins whose levels differed between samples
from patients with stage II and III CRC in one primary tumor location
only. Additional file 10A shows the 44 proteins whose levels differed
between stage II and III samples from patients with right-sided CRC only,
Additional file 10B shows the 11 proteins whose levels differed between
stage II and III samples from patients with left-sided CRC only, and
Additional file 10C shows the 30 proteins whose levels differed between
stage II and III samples from patients with rectal cancer only. Accession,
peptide count, unique peptides, confidence score, protein name, and
gene name are given in the tables. (XLSX 16 kb)
Additional file 11 The proteins whose levels differed between samples
from patients with stage II and III CRC in two primary tumor locations.
Additional file 11A shows the 33 proteins whose levels differed between
stage II and III samples from patients with cancer in the right colon and
rectum, Additional file 11B shows the 7 proteins whose levels differed
between stage II and III samples from patients with cancer in the right
and left colon, and Additional file 11C shows the 7 proteins whose levels
differed between stage II and III samples from patients with cancer in the
left colon and rectum. Accession, peptide count, unique peptides,
confidence score, protein name, and gene name are given in the tables.
(XLSX 14 kb)
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